Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives $10.00 Average Target Price from Analysts

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) have been given a consensus rating of “Buy” by the eight research firms that are covering the stock, Marketbeat.com reports. Eight research analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $10.00.

Several equities analysts have recently weighed in on CMPX shares. LADENBURG THALM/SH SH assumed coverage on shares of Compass Therapeutics in a report on Tuesday, March 15th. They set a “buy” rating and a $7.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Compass Therapeutics in a report on Monday, May 23rd.

In related news, CEO Thomas J. Schuetz acquired 27,836 shares of the stock in a transaction that occurred on Tuesday, May 10th. The stock was purchased at an average price of $1.80 per share, with a total value of $50,104.80. Following the transaction, the chief executive officer now owns 5,153,303 shares of the company’s stock, valued at approximately $9,275,945.40. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Thomas J. Schuetz acquired 18,355 shares of the stock in a transaction that occurred on Monday, May 23rd. The shares were bought at an average cost of $2.72 per share, with a total value of $49,925.60. Following the transaction, the chief executive officer now directly owns 5,191,873 shares in the company, valued at approximately $14,121,894.56. The disclosure for this purchase can be found here. In the last three months, insiders bought 342,525 shares of company stock valued at $725,478.

A number of hedge funds have recently modified their holdings of CMPX. Difesa Capital Management LP purchased a new position in Compass Therapeutics in the 4th quarter valued at approximately $33,000. Millennium Management LLC acquired a new stake in shares of Compass Therapeutics in the 4th quarter valued at $35,000. Mirabella Financial Services LLP acquired a new stake in shares of Compass Therapeutics in the 4th quarter valued at $60,000. Qube Research & Technologies Ltd raised its holdings in shares of Compass Therapeutics by 81.9% in the 1st quarter. Qube Research & Technologies Ltd now owns 52,842 shares of the company’s stock valued at $72,000 after purchasing an additional 23,789 shares in the last quarter. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Compass Therapeutics in the 4th quarter valued at $75,000. 66.04% of the stock is owned by institutional investors.

NASDAQ:CMPX opened at $2.13 on Wednesday. The company has a 50 day moving average price of $2.10 and a 200-day moving average price of $2.02. Compass Therapeutics has a 1-year low of $1.25 and a 1-year high of $5.80.

Compass Therapeutics (NASDAQ:CMPX – Get Rating) last posted its earnings results on Monday, May 9th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.07. Analysts expect that Compass Therapeutics will post -0.35 earnings per share for the current fiscal year.

About Compass Therapeutics (Get Rating)

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in Phase II clinical trial for biliary tract cancers, as well as Phase Ib clinical trial for colorectal and ovarian cancer; CTX-471, a monoclonal antibody product candidate that is in Phase I clinical trial for patients with solid tumors, such as small cell lung cancer and melanoma; and CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 for oncology area.

Featured Stories